<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Raloxifene: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Raloxifene: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Raloxifene: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11017" href="/d/html/11017.html" rel="external">see "Raloxifene: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709396"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased risk of VTE:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene. Women with active or past history of VTE should not take raloxifene.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or increased risk for major coronary events. Consider the risk-benefit balance in women at risk for stroke.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24673709"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Evista</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868116"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Raloxifene;</li>
<li>APO-Raloxifene;</li>
<li>Evista;</li>
<li>PMS-Raloxifene [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F217113"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Selective Estrogen Receptor Modulator (SERM)</li></ul></div>
<div class="block doa drugH1Div" id="F217087"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9f9404a-881f-44e5-b401-a29892cf1625">Osteoporosis, postmenopausal, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, fracture risk reduction (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used to reduce the risk of vertebral fracture in patients in whom first-line therapies are not appropriate, or in patients who are also at increased risk of invasive breast cancer; use has not been associated with reduction in hip or nonvertebral fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-34448749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-34448749'])">Ref</a></span>). Prior to use, evaluate and treat any potential causes of secondary osteoporosis (eg, severe vitamin D deficiency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25182228'])">Ref</a></span>). Ensure adequate calcium and vitamin D intake during therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Discontinuation of therapy: </b>If continued osteoporosis therapy is necessary after discontinuation, switch to antiresorptive therapy (eg, with a bisphosphonate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-34448749','lexi-content-ref-16059623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-34448749','lexi-content-ref-16059623'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dff8ec24-9ad7-40c0-b50a-54deb2a3c65e">Risk reduction for invasive breast cancer in postmenopausal females</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Risk reduction for invasive breast cancer in postmenopausal females:</b>
<b>Oral:</b> 60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy for breast cancer risk reduction:</i> 5 years; may be used longer than 5 years in females with osteoporosis where breast cancer risk reduction is a secondary benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31479306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31479306'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990706"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">CrCl ≤50 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988046"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.</p></div>
<div class="block doe drugH1Div" id="F217088"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F217053"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (3% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (8% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (11% to 16%), leg cramps (≤12%), muscle spasm (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (14% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (3%), syncope (&lt;2%), venous thromboembolism (1% to 2%; includes deep vein thrombosis, pulmonary embolism, retinal vein thrombosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Insomnia (6%), hypoesthesia (&lt;2%), neuralgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6%), diaphoresis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7%), vomiting (5%), gastrointestinal disease (3%), flatulence (2% to 3%), gastroenteritis (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginal hemorrhage (3% to 6%), mastalgia (4%), leukorrhea (3%), urinary tract abnormality (3%), uterine disease (3%), endometrium disease (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (8%), tendinopathy (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (10%), sinusitis (10%), pharyngitis (8%), pneumonia (3%), laryngitis (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cerebrovascular accident, decreased LDL cholesterol (Delmas 1997; Walsh 1998), decreased serum cholesterol (Delmas 1997; Walsh 1998), decreased serum fibrinogen (Walsh 1998), hypertriglyceridemia (in women with a history of increased triglycerides in response to oral estrogens), retinal vein occlusion, superficial thrombophlebitis</p></div>
<div class="block coi drugH1Div" id="F217065"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of or current venous thromboembolic disorders (including DVT, PE, and retinal vein thrombosis); pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i> (additional contraindications not in US labeling): Hypersensitivity to raloxifene or any component of the formulation; patients of childbearing potential.</p></div>
<div class="block war drugH1Div" id="F217050"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b>[US Boxed Warning]: Raloxifene may increase the risk for deep vein thrombosis (DVT) and pulmonary embolism (PE); use is contraindicated in patients with history of or current venous thromboembolic disorders</b> (including DVT, PE, or retinal vein thrombosis). Consider risks versus benefits in females at risk for thromboembolism (heart failure [HF], superficial thrombophlebitis, active malignancy). The risk for DVT and PE are higher during the first 4 months of treatment. Superficial thrombophlebitis has also been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer history: The use of raloxifene has not been adequately studied in females with a prior history of breast cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: <b>[US Boxed Warning]: The risk of death due to stroke is increased in postmenopausal females with coronary heart disease or at increased risk for major coronary events; consider risks versus benefits in females at risk for stroke.</b> Do not use for primary or secondary prevention of cardiovascular disease. Assess risks versus benefits in females at risk for stroke (eg, prior stroke, transient ischemic attack, atrial fibrillation, hypertension, smokers).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; safety and efficacy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertriglyceridemia: Females with a history of marked elevated triglycerides (&gt;5.6 mmol/L or &gt;500 mg/dL) in response to treatment with oral estrogens (or estrogen/progestin) may also develop elevated triglycerides when treated with raloxifene; monitor triglycerides.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate to severe renal impairment; safety and efficacy have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Uterine bleeding: Investigate unexplained uterine bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Estrogens: Concurrent use with systemic estrogen therapy is not recommended; safety has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Males: Safety and efficacy have not been established in men. Raloxifene is not indicated for use in men.</p>
<p style="text-indent:-2em;margin-left:4em;">• Premenopausal females: Safety has not been established in premenopausal females; use is not indicated and not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Raloxifene does not eliminate the risk of breast cancer; investigate unexplained breast abnormality that occurs during treatment. Raloxifene is not indicated for treatment of invasive breast cancer, to reduce the risk of recurrence of invasive breast cancer, or to reduce the risk of noninvasive breast cancer. The efficacy (for breast cancer risk reduction) in females with inherited BRCA1 and BRCA1 mutations has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged immobilization: Discontinue raloxifene at least 72 hours prior to and during prolonged immobilization (postoperative recovery or prolonged bed rest); restart only once patient fully ambulatory. Advise patients to move periodically during prolonged travel.</p></div>
<div class="block foc drugH1Div" id="F24673710"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evista: 60 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg</p></div>
<div class="block geq drugH1Div" id="F217046"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F217068"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Evista Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $7.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Raloxifene HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.53 - $8.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868117"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evista: 60 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg</p></div>
<div class="block adm drugH1Div" id="F2930855"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">May be administered at any time of day without regard to meals.</p></div>
<div class="block hazard drugH1Div" id="F49104572"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F7885625"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088593.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRlVhvYsc7EvEoBY1Oxvw10oQ%3D%3D&amp;TOPIC_ID=9593" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088593.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F217062"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, fracture risk reduction:</b> Treatment and prevention of postmenopausal osteoporosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Risk reduction for invasive breast cancer:</b> Risk reduction of invasive breast cancer in postmenopausal females with osteoporosis; risk reduction of invasive breast cancer in postmenopausal females with high risk for invasive breast cancer (high risk is defined as at least 1 breast biopsy showing lobular carcinoma in situ or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer 1.66% or more [based on the modified Gail model]; factors included in the modified Gail model include current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity, or age of first live birth).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Raloxifene does not eliminate the risk of breast cancer; patients should have a breast exam and mammogram prior to initiating raloxifene and continue regular breast exams and mammograms as per current guideline recommendations. Raloxifene is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence. Raloxifene is not indicated for the reduction of the risk of noninvasive breast cancer. There are no data available regarding the effect of raloxifene on invasive breast cancer incidence in females with inherited mutations BRCA1, BRCA2 to be able to make specific recommendations on the effectiveness of raloxifene.</p></div>
<div class="block mst drugH1Div" id="F217119"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Evista may be confused with Eovist</p>
<p style="text-indent:-2em;margin-left:4em;">Raloxifene may be confused with ospemifene, toremifene</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Evista brand name for raloxifene [US, Canada, and multiple international markets] may be confused with Avinza brand name for morphine [Puerto Rico] and Invanz brand name for ertapenem [US, Canada, Qatar]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299977"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F217055"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Raloxifene. Management: Consider separating the doses of raloxifene and bile acid sequestrants by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the adverse/toxic effect of Raloxifene.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluoroestradiol F18: Selective Estrogen Receptor Modulators may diminish the diagnostic effect of Fluoroestradiol F18.  Management: Image patients with fluoroestradiol F-18 prior to starting systemic endocrine therapies that block the estrogen receptor. Use of fluoroestradiol F-18 should not delay indicated treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Raloxifene may decrease the absorption of Levothyroxine.  Management: Consider separating doses of raloxifene and levothyroxine by several hours. Monitor for reduced effects of levothyroxine and reduced serum concentrations of thyroxine if raloxifene and levothyroxine are used concomitantly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Raloxifene may diminish the anticoagulant effect of Vitamin K Antagonists. Raloxifene may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49321704"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Raloxifene is not indicated for use in females of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F217069"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Raloxifene is contraindicated during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F20548218"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if raloxifene is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene is not indicated for use in females of reproductive potential.</p></div>
<div class="block dic drugH1Div" id="F2930854"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Osteoporosis prevention or treatment: Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Females and males should consume:</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: 800 to 1,000 units daily (age ≥50 years) (NOF [Cosman 2014]). Recommended dietary allowance (RDA): 600 units daily (age ≤70 years) <b>or</b> 800 units daily (age ≥71 years) (IOM 2011).</p></div>
<div class="block mop drugH1Div" id="F217058"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Lipid profile (in females at risk for hypertriglyceridemia); mammogram and breast exam (prior to and regularly during treatment).</p>
<p style="text-indent:-2em;margin-left:2em;">Osteoporosis: Serial bone mineral density (BMD) should be evaluated at baseline and every 1 to 3 years (usually at ~2 years following initiation of therapy, then more or less frequently depending on patient-specific factors and stability of BMD) (AACE/ACE [Camacho 2020]; ES [Eastell 2019]; NOF [Cosman 2014]); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider monitoring biochemical markers of bone turnover (eg, fasting serum CTX or urinary NTX) at baseline, 3 months, and 6 months, to assess treatment response and adherence to therapy (ES [Eastell 2019]).</p></div>
<div class="block pha drugH1Div" id="F217049"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Raloxifene is an estrogen agonist/antagonist (a selective estrogen receptor modulator [SERM]); selective binding activates estrogenic pathways in some tissues and antagonizes estrogenic pathways in other tissues. Raloxifene acts like an estrogen agonist in the bone to prevent bone loss and has estrogen antagonist activity to block some estrogen effects in the breast and uterine tissues. Raloxifene decreases bone resorption, increasing bone mineral density and decreasing fracture incidence.</p></div>
<div class="block phk drugH1Div" id="F217064"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid; ~60% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 2,348 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Highly protein bound (95% to albumin and α-glycoprotein); does not bind to sex-hormone-binding globulin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic, extensive first-pass metabolism; metabolized to glucuronide conjugates</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~2% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 27.7 hours (following a single dose); 32.5 hours (following multiple doses)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (primarily); urine (&lt;0.2% as unchanged drug; &lt;6% as glucuronide conjugates)</p></div>
<div class="block phksp drugH1Div" id="F51220361"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Raloxifene AUC was 122% higher in patients with moderate to severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Raloxifene apparent clearance was reduced 56% and plasma concentrations were increased 150% in patients with mild hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F217070"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Loxifen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifen stada | Raloxifen Teva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-raloxifene | Chemmart raloxifene | Evifyne | Evista | Fixta | Ralovista | Raloxifene amneal | Raloxifene an | Raloxifene gh | Terry white chemists raloxifene</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aloxif | Oxilar | Ralox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifene eg | Raloxifene mithra | Raloxifene teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de raloxifeno | Evista</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bei bang | Evista</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Evista | Maxeno | Raloxifeno clorhidrato</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifen Teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Evista | Optruma | Raloxifen AL | Raloxifen stada | Raloxifene teva | Raloxifenhydrochlorid axcount</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Evista | Loxifen | Raloxib | Raloxifran</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Evista | Optruma</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Evista | Osteo | Ralogen | Ralox | Sedovesta</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Raloxifeno aurobindo | Raloxifeno aurovitas | Raloxifeno Cinfa | Raloxifeno Kern pharma | Raloxifeno mylan | Raloxifeno Ratiopharm | Raloxifeno Sandoz | Raloxifeno Stada | Raloxifeno tarbis | Raloxifeno Tecnigen | Raloxifeno Teva | Raloxifeno vir</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Evista | Optruma</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Evista | Optruma | Ralopharm | Raloxifene arrow | Raloxifene Biogaran | Raloxifene cristers | Raloxifene eg | Raloxifene mylan | Raloxifene sandoz | Raloxifene teva | Raloxifene zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Evirex | Evista | Ostiral | Raloxifene | Raloxifene teva | Razylan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Evista | Ostiral | Razylan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-raloxifene | Evista</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Clastellos | Evista | Raloxa | Raloxibone | Raloxifen actavis</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bonebay | Bonmax | Esserm | Estoral | Estroact | Evomate | Fiona | Gynista | Osral | Posmo | Ralista | Ralocium | Ralofen | Ralosto | Ralotab | Rolofen | Ronal | Ruftuf | Sermifen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Evista | Optruma | Raloxifene sandoz</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifene hydrochloride nissin | Raloxifene hydrochloride towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bonmax | Evista</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daewoong raloxifene | Eloxifen | Eviehill | Eviqueen | Evira | Evista | Evistan | Evixifen | Inist raloxifene hcl | Laroxyfen | Loxista | New avesta | Queensta | Raboni | Ralofene | Raloxfen | Raloxi | Raloxiqueen | Raloxta | Raloxufen | Ralxipenem | Ravista | Raxifene | Seoul raloxifene hci</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Evista | Osteya | Raloxifene</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alvisver | Boganash | Canzefhin | Eilen | Ersentilex | Evista | Fezicrel | Raloxifeno | Ulos h | Zotralox</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bonmax | Elasta | Evista</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifeen HCl Aurobindo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Evista | Ralox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anserm | Evista | Larfen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Evista | Loxiam | Osteonil | Relofin | Roxista</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifene HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifeno aurobindo | Raloxifeno ciclum | Raloxifeno Generis | Raloxifeno Germed | Raloxifeno Labesfal | Raloxifeno mylan | Raloxifeno Sandoz | Raloxifeno Teva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Evista | Optruma</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-raloxifene | Evista</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxife teva | Raloxifen ebb | Raloxifen stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxon</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxifene teva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Celvista</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Evista</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Evista | Ralien</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Evista | Raloxy</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ondamax | Raxeto</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Evista</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16837676">
<a name="16837676"></a>Barrett-Connor E, Mosca L, Collins P, et al, “Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women,” <i> N Engl J Med</i>, 2006, 355(2):125-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16837676/pubmed" id="16837676" target="_blank">16837676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9385122">
<a name="9385122"></a>Delmas PD, Bjarnason NH, Mitlak BH, et al, “Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women,” <i>N Engl J Med</i>, 1997, 337(23):1641-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/9385122/pubmed" id="9385122" target="_blank">9385122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8725181">
<a name="8725181"></a>Draper MW, Flowers DE, Huster WJ, et al, “A Controlled Trial of Raloxifene (LY139481) HCl: Impact on Bone Turnover and Serum Lipid Profile in Healthy Postmenopausal Women,” <i>J Bone Miner Res</i>, 1996, 11(6):835-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/8725181/pubmed" id="8725181" target="_blank">8725181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Evista.1">
<a name="Evista.1"></a>Evista (raloxifene) [prescribing information]. Indianapolis, IN: Lilly USA LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Evista.2">
<a name="Evista.2"></a>Evista (raloxifene) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16754728">
<a name="16754728"></a>Land SR, Wickerham DL, Costantino JP, et al, “Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,” <i>JAMA</i>, 2006, 295(23):2742-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16754728/pubmed" id="16754728" target="_blank">16754728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15572757">
<a name="15572757"></a>Martino S, Cauley JA, Barrett-Connor E, et al, “Continuing Outcomes Relevant to Evista: Breast Cancer Incident in Postmenopausal Women in a Randomized Trial of Raloxifene,” <i>J Natl Cancer Inst</i>, 2004, 96(23):1751-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/15572757/pubmed" id="15572757" target="_blank">15572757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prasco.1">
<a name="Prasco.1"></a>Raloxifene [prescribing information]. Mason, OH: Prasco Laboratories; August 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16059623">
<a name="16059623"></a>Siris ES, Harrris ST, Eastell R, et al, “Skeletal Effects of Raloxifene After 8 Years: Results From the Continuing Outcomes Relevant to Evista (CORE) Study,” <i>J Bone Miner Res</i>, 2005, 20(9):1514-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16059623/pubmed" id="16059623" target="_blank">16059623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31479306">
<a name="31479306"></a>Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. <i>J Clin Oncol.</i> 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/31479306/pubmed" id="31479306" target="_blank">31479306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16754727">
<a name="16754727"></a>Vogel VG, Costantino JP, Wickerham DL, “Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,” <i>JAMA</i>, 2006, 295(23):2727-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/16754727/pubmed" id="16754727" target="_blank">16754727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9600478">
<a name="9600478"></a>Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. <i>JAMA</i>. 1998;279(18):1445-1451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/raloxifene-drug-information/abstract-text/9600478/pubmed" id="9600478" target="_blank">9600478</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9593 Version 310.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
